ESLIM-01 is a randomized, double-blinded, placebo-controlled Phase III trial in
(C) 2024 Electronic News Publishing, source
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
291 GBX | -1.36% | -3.33% | +2.47% |
ESLIM-01 is a randomized, double-blinded, placebo-controlled Phase III trial in
(C) 2024 Electronic News Publishing, source
1st Jan change | Capi. | |
---|---|---|
+2.47% | 3.2B | |
+40.73% | 739B | |
+31.77% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+14.79% | 240B | |
+9.52% | 210B | |
-4.95% | 206B | |
+6.17% | 164B |